COMPANY

Rise Therapeutics

Keywords: oncology immunology synthetic biology autoimmune diseases cancer Sjogren's Syndrome Acute Respiratory Distress Syndrome Ulcerative Colitis Rheumatoid Arthritis Type 1 Diabetes clostridium difficile infection inflammatory bowel disease multiple sclerosis Sjögren Unspecified Sjögren Syndrome Melanoma Basal Cell Cancer Squamous Cell Cancer Adenoma Crohn Disease Ulcerative Colitis Chronic Mild Ulcerative Colitis Chronic Moderate Ulcerative Colitis Chronic COPD (Chronic Obstructive Pulmonary Disease) COPD Exacerbation COPD Exacerbation Acute Type 1 Diabetes (Juvenile Onset) Type 1 Diabetes Mellitus R-3750 R-2487 R-5780 R-5280

Profile checked Oct 10, 2026

8Trials (company is sponsor)40NIH grants

Funding and NIH signals

NIH award NIH awarded $740K (SBIR Phase II 1R44CA306440-01A1, new, notice Sep 16, 2026); 5 NIH awards totaling $4.11M in the last 12 months. NIH RePORTER 1R44CA306440-01A1 (Sep 16, 2026)
Evidence (5 events)
- Sep 16, 2026 · NIH RePORTER 1R44CA306440-01A1
  Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 1R44CA306440-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 740140; Administering IC: National Cancer Institute; Project title: Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors; Organization type: Domestic For-Profits
- Sep 3, 2026 · NIH RePORTER 1R44DK146369-01
  Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 1R44DK146369-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1042478; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease; Organization type: Domestic For-Profits
- Sep 1, 2026 · NIH RePORTER 4UH3DE034134-02
  Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 4UH3DE034134-02; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 549833; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome; Organization type: Domestic For-Profits
- Jul 28, 2026 · NIH RePORTER 5R44AG084484-04
  Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 5R44AG084484-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 967715; Administering IC: National Institute on Aging; Project title: A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis; Organization type: Domestic For-Profits
- Jul 16, 2026 · NIH RePORTER 5SB1DK141356-03
  Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 5SB1DK141356-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 811362; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Nov 1, 2026 Trial start Phase 1: R-2487 in Patients With Sjogren's Syndrome (SS) source ↗
Nov 1, 2026 Trial start Phase 1: R-3750 in Patients With Crohn's Disease source ↗
Sep 16, 2026 Grant Government grant — SBIR: $740,140 (annual award, as published), announced Sep 16, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 3, 2026 Grant Government grant — SBIR: $1.04M (annual award, as published), announced Sep 3, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 1, 2026 Grant Government grant — NIH UH3: $549,833 (annual award, as published), announced Sep 1, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
Sep 1, 2026 Trial start Phase 1: R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS) source ↗
Sep 1, 2026 Trial start Phase 1: A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD source ↗
Jul 28, 2026 Grant Government grant — SBIR: $967,715 (annual award, as published), announced Jul 28, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Jul 16, 2026 Grant Government grant — SBIR: $811,362 (annual award, as published), announced Jul 16, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 14, 2025 Grant Government grant — NIH UG3: $429,158 (annual award, as published), announced Aug 14, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
Aug 5, 2025 Grant Government grant — SBIR: $952,967 (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Aug 1, 2025 Trial start Phase 1: R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors source ↗
Jul 16, 2025 Grant Government grant — SBIR: $827,713 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 11, 2025 Grant Government grant — SBIR: $704,565 (annual award, as published), announced Jul 11, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
Dec 5, 2023 Trial start Phase 1: R-5280 in Newly Diagnosed Patients With Type 1 Diabetes source ↗
Oct 19, 2023 Trial start Phase 1: R-2487 in Patients With Rheumatoid Arthritis source ↗
Feb 27, 2023 Trial start Phase 1: R-3750 in Patients With Mild to Moderate Ulcerative Colitis source ↗

Upcoming milestones

Nov 30, 2026 (ESTIMATED) · Phase 1 · R-2487 in Patients With Rheumatoid Arthritis · NCT05961592
Apr 30, 2028 (ESTIMATED) · Phase 1 · A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD · NCT07076290
Oct 31, 2028 (ESTIMATED) · Phase 1 · R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS) · NCT07646028
Dec 31, 2028 (ESTIMATED) · Phase 1 · R-3750 in Patients With Crohn's Disease · NCT07791888
Mar 15, 2029 (ESTIMATED) · Phase 1 · R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors · NCT06398418
Aug 30, 2029 (ESTIMATED) · Phase 1 · R-2487 in Patients With Sjogren's Syndrome (SS) · NCT06297213

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 16, 2026 Government grant — SBIR: $740,140 (annual award, as published), announced Sep 16, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 3, 2026 Government grant — SBIR: $1.04M (annual award, as published), announced Sep 3, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 1, 2026 Government grant — NIH UH3: $549,833 (annual award, as published), announced Sep 1, 2026. Agency: NIH/NIDCR. Source: government award database. source ↗
Jul 28, 2026 Government grant — SBIR: $967,715 (annual award, as published), announced Jul 28, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Jul 16, 2026 Government grant — SBIR: $811,362 (annual award, as published), announced Jul 16, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 14, 2025 Government grant — NIH UG3: $429,158 (annual award, as published), announced Aug 14, 2025. Agency: NIH/NIDCR. Source: government award database. source ↗
Aug 5, 2025 Government grant — SBIR: $952,967 (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Jul 16, 2025 Government grant — SBIR: $827,713 (annual award, as published), announced Jul 16, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 11, 2025 Government grant — SBIR: $704,565 (annual award, as published), announced Jul 11, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT06297213	R-2487 in Patients With Sjogren's Syndrome (SS)	Phase 1	Not yet recruiting	Nov 1, 2026	Aug 30, 2029 (estimated)
NCT06398418	R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors	Phase 1	Recruiting	Aug 1, 2025	Mar 15, 2029 (estimated)
NCT07791888	R-3750 in Patients With Crohn's Disease	Phase 1	Not yet recruiting	Nov 1, 2026	Dec 31, 2028 (estimated)
NCT07646028	R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)	Phase 1	Not yet recruiting	Sep 1, 2026	Oct 31, 2028 (estimated)
NCT05666960	R-3750 in Patients With Mild to Moderate Ulcerative Colitis	Phase 1	Recruiting	Feb 27, 2023	2026-07 (estimated)
NCT05961592	R-2487 in Patients With Rheumatoid Arthritis	Phase 1	Recruiting	Oct 19, 2023	Nov 30, 2026 (estimated)
NCT07076290	A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD	Phase 1	Not yet recruiting	Sep 1, 2026	Apr 30, 2028 (estimated)
NCT06057454	R-5280 in Newly Diagnosed Patients With Type 1 Diabetes	Phase 1	Completed	Dec 5, 2023	Nov 5, 2025 (actual)

NIH awards 40

Annual award amounts. Total $28.7M.

Sep 16, 2024 NIH award 1SB1DK141356-01 FY2024: $673,379 awarded for that fiscal year; activity SB1 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Synthetically Engineered Oral Immuno source ↗
Aug 21, 2024 NIH award 5R44DK137649-02 FY2024: $995,869 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. R-5280, A Novel Modified Superi source ↗
Jul 26, 2024 NIH award 5R44DK133061-03 FY2024: $914,660 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological-Directed Live Biothera source ↗
Jul 22, 2024 NIH award 4R44AI174844-02 FY2024: $956,049 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological-Directed source ↗
Jun 26, 2024 NIH award 5R44CA261509-04 FY2024: $171,480 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Microbiome-Based Immune-Modulator th source ↗
Jun 6, 2024 NIH award 4R44AG084484-02 FY2024: $987,225 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological-Directed Biotherapy fo source ↗
Dec 7, 2023 NIH award 5R44AI174332-02 FY2024: $984,405 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Synthetic Biology-Deriv source ↗
Sep 4, 2023 NIH award 1R44AG084484-01 FY2023: $494,488 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological-Directed Biotherapy fo source ↗
Aug 11, 2023 NIH award 1R44DK137649-01 FY2023: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. R-5280, A Novel Modified Supe source ↗
Jul 26, 2023 NIH award 4R44DK133061-02 FY2023: $1,001,952 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological-Directed Live Biothe source ↗
Jun 22, 2023 NIH award 5R44DK134274-02 FY2023: $983,580 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunologically Directe source ↗
Jun 2, 2023 NIH award 5R44CA261509-03 FY2023: $828,114 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Microbiome-Based Immune-Modulator th source ↗
Apr 26, 2023 NIH award 5SB1DE030833-03 FY2023: $947,701 awarded for that fiscal year; activity SB1 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Probiotic for the Treatment of Sjogr source ↗
Apr 24, 2023 NIH award 1R44AI174844-01A1 FY2023: $306,499 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological-Directe source ↗
Jan 17, 2023 NIH award 1R44AI174332-01 FY2023: $1,026,596 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Synthetic Biology-Der source ↗
Jan 10, 2023 NIH award 5R44AI157031-03 FY2023: $922,693 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunologically Enhanced Probiotic f source ↗
Sep 1, 2022 NIH award 3R44DK134274-01S1 FY2022: $78,120 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunologically Direct source ↗
Jul 15, 2022 NIH award 1R43TR004300-01 FY2022: $282,514 awarded for that fiscal year; activity R43 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Probiotic Drug Delivery source ↗
Jul 4, 2022 NIH award 1R44DK133061-01A1 FY2022: $360,624 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological-Directed Live Biothe source ↗
Jul 1, 2022 NIH award 4R44CA261509-02 FY2022: $1,049,717 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Microbiome-Based Immune-Modulator source ↗
Jun 24, 2022 NIH award 1R44DK134274-01 FY2022: $1,021,316 awarded for that fiscal year; activity R44 (SBIR); PI FURLAN FREGUIA, CHRISTIAN; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunologically Direc source ↗
Jun 3, 2022 NIH award 5R44AI152670-03 FY2022: $973,438 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Engineered Probiotic for the Prevent source ↗
Apr 27, 2022 NIH award 5SB1DE030833-02 FY2022: $972,063 awarded for that fiscal year; activity SB1 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Probiotic for the Treatment of Sjogr source ↗
Apr 6, 2022 NIH award 3R44DK117726-04S1 FY2022: $30,223 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological Probiotic for Treatin source ↗
Apr 5, 2022 NIH award 5R44DK117726-04 FY2022: $459,043 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological Probiotic for Treating source ↗
Feb 7, 2022 NIH award 3R44DK117726-03S1 FY2022: $24,936 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunological Probiotic for Treatin source ↗
Jan 10, 2022 NIH award 5R44AI157031-02 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Immunologically Enhanced Probiotic source ↗
Jun 29, 2021 NIH award 5R44AI152670-02 FY2021: $913,769 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Engineered Probiotic for the Prevent source ↗
May 12, 2021 NIH award 1SB1DE030833-01A1 FY2021: $998,658 awarded for that fiscal year; activity SB1 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Probiotic for the Treatment of Sjo source ↗
Mar 31, 2021 NIH award 1R44CA261509-01 FY2021: $386,860 awarded for that fiscal year; activity R44 (SBIR); PI FANGER, GARY; recipient as written: RISE THERAPEUTICS, LLC, Rockville, MD. A Novel Microbiome-Based Immune-Modulator th source ↗